Your Health, We Care
Release date: 2024-11-11 14:01:19 Recommended: 109
The neoadjuvant regimen of Pralsetinib is primarily based on its significant efficacy in RET fusion-positive tumors. Neoadjuvant therapy refers to adjuvant therapy given prior to surgery or primary therapy to reduce tumor size, reduce tumor stage, improve surgical success, or reduce the risk of postoperative recurrence.
Although there is no unified standardized regimen for the neoadjuvant treatment of pratinib, it can be summarized based on existing clinical studies and practical experience:
Neoadjuvant treatment of pratinib is mainly suitable for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC) and papillary thyroid carcinoma (PTC) with positive RET fusion.
The patient should be histologically or cytologically confirmed, and the status of RET fusion should be confirmed by molecular testing.
The recommended dose of pratinib is 400 mg daily administered orally.
It should be taken at the same time every day on an empty stomach, and should not be eaten at least 2 hours before and at least 1 hour after consumption.
The cycle of neoadjuvant therapy is usually determined based on the patient's specific situation and tumor response, and may include treatment durations ranging from weeks to months.
During treatment, imaging tests (e.g., CT, MRI, etc.) should be performed regularly to assess the response of the tumor.
Depending on how well the tumor is shrinking and how well the patient tolerates, your doctor may adjust your treatment regimen, including increasing or decreasing the dose or lengthening/shortening the duration of treatment.
After neoadjuvant therapy is completed, surgical resection should be performed as soon as possible if the tumor has shrunk and the patient is eligible for surgery.
Laptinib or other adjuvant therapies may need to be continued postoperatively on a case-by-case basis to reduce the risk of recurrence.
During neoadjuvant therapy, patients should be closely monitored for adverse events such as hypertension, fatigue, musculoskeletal pain, diarrhea, and other common adverse events.
Possible serious adverse events, such as interstitial lung disease/pneumonia, should be treated and intervened in a timely manner.
It is important to note that the neoadjuvant regimen of pratinib should be individualized to the specific situation of the patient and should be carried out under the guidance of an experienced physician. In addition, with the deepening of clinical research and the accumulation of experience, the neoadjuvant treatment regimen of pratinib may also be updated and improved.
